Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 22 February 2002:
Vol. 295. no. 5559, p. 1444
DOI: 10.1126/science.295.5559.1444a
Prev | Table of Contents | Next

News of the Week

CANCER RESEARCH:
Obstacle for Promising Cancer Therapy

Jean Marx

Angiogenesis inhibitors, which aim to treat cancer by preventing the growth of the new blood vessels needed to nourish tumors, are being widely tested around the world. But new work suggests that tumors may be able to get around angiogenesis inhibitors, just as they do older chemotherapeutic drugs. Researchers report on page 1526 that tumors in which the p53 tumor suppressor gene has been inactivated--which happens in about 50% of human cancers--are much less responsive to angiogenesis inhibitors than are comparable tumors in which the gene is still functional. Loss of p53 apparently renders tumor cells better able to survive in the low-oxygen conditions present in tumors deprived of an ample blood supply by antiangiogenesis treatment.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)